A Study of Mesenchymal Stem Cell in the Treatment of Autism Spectrum Disorder
NCT ID: NCT07177677
Last Updated: 2025-09-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE1
42 participants
INTERVENTIONAL
2025-09-30
2028-08-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
hCT-MSC Infusion in Adults With Autism Spectrum Disorder
NCT04484077
Stem Cell Therapy in Autism Spectrum Disorders
NCT01974973
hCT-MSCs for Children With Autism Spectrum Disorder (ASD)
NCT03099239
Autologous Bone Marrow Stem Cell Therapy for Autism
NCT02627131
Allogeneic Umbilical Cord Mesenchymal Stem Cell Therapy for Autism
NCT02192749
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
hBMMSC 0.5×10^6 cells/kg
human Bone Marrow Mesenchymal Stem Cell (hBMMSC) 0.5×10\^6 cells/kg、 1.0×10\^6 cells/kg、 2.0×10\^6 cells/kg
hBMMSC
Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
hBMMSC
Group 1: 0.5×10\^6 cells/kg (participant's body weight) single dose; Group 2: 1.0×10\^6 cells/kg (participant's body weight) single dose; Group 3: 2.0×10\^6 cells/kg (participant's body weight) single dose.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Body weight ≥ 17 kg
* Meets the diagnostic criteria for Autism Spectrum Disorder (ASD) as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), and confirmed by the Autism Diagnostic Interview-Revised (ADI-R) and the Autism Diagnostic Observation Schedule-2 (ADOS-2)
* Has either not received any psychotropic medication in the three months prior to enrollment or has been on a stable regimen of psychotropic medication for at least three months
* The subject and/or their legal guardian(s) agree to participate in the trial and provide signed informed consent.
Exclusion Criteria
* Active infection (viral, bacterial, fungal, or mycobacterial)
* A confirmed diagnosis of Rett syndrome, childhood disintegrative disorder, fragile X syndrome, or other genetic/metabolic diseases that may impact cognitive development
* History of epileptic seizures within 6 months prior to enrollment
* History of suicide attempts/self-harm, presentation of suicidal ideation, or being judged as the risk of suicidal by the investigator
* Severe hematologic diseases or active malignancy
* Severe hepatic or renal disease
* Participation in a drug clinical trial within 3 months prior to enrollment (unless beyond the protocol-defined wash-out period) or participation in any other stem cell study within the past year
* A positive skin test result
* Any other condition which, in the opinion of the investigator, would make the subject unsuitable for participation in this study
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Capital Medical University
OTHER
Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MKMSC-CT-003-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.